Innovator. Advocate.Together with patients, on a mission to advance transformative treatments for people living with serious and rare diseases.
Now approved in the EU. Click here for full summary of product characteristics.
Waylivra is not approved for any use and is not commercially available in the United States or other markets outside the European Union.
Our Commitment
At Akcea, we’re on a mission to transform the treatment of unaddressed or under-addressed serious and rare diseases with leading-edge, RNA-targeted medicines. Whether you’re a patient living with a serious condition, or a physician whose patient desperately needs a therapy, we know you’re counting on us, and it fuels our unwavering commitment to be a partner to the community through innovation.
Our Programs
Cardiometabolic Lipid Disorders
These disorders are complex, with a multitude of risk factors related to many diseases, rare and relatively common, including pancreatitis, diabetes, liver disease, and multiple forms of cardiovascular disease.
Hereditary Transthyretin (TTR) Amyloidosis
TTR amyloidosis (ATTR) is a rare, progressive and fatal genetic disease that currently only has limited treatment options that do not treat the underlying cause of disease.
News
June 26, 2019
Akcea and Ionis Announce Upcoming Data Presentations at the 5th European Academy of Neurology Annual Congress
June 20, 2019
Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting
Learning about hereditary transthyretin (TTR) amyloidosis
TTR amyloidosis (ATTR) is a rare, progressive and fatal genetic disease that currently only has limited treatment options that do not treat the underlying cause of disease.
Visit hattrchangethecourse.comLearning about familial chylomicronemia syndrome (FCS)
FCS is a severe and rare disease caused by an enzyme deficiency that leads to the buildup of chylomicrons and a high risk of life-threatening pancreatitis
Visit FCSFocus.com
